following a full submission:
mavacamten (Camzyos®) is accepted for use within NHSScotland.
Indication Under Review: treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.
In a double-blind, randomised, phase III study, the proportion of patients who achieved the composite primary outcome (that assessed exercise capacity and NYHA class) was significantly greater in the mavacamten group compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- mavacamten (Camzyos)
- SMC ID:
- SMC2618
- Indication:
For treatment of symptomatic (New York Heart Association, NYHA, class II III) obstructive hypertrophic cardiomyopathy (HOCM) in adult patients.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 April 2024